TOP TEN perturbations for 1552889_a_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1552889_a_at
Selected probe(set): 1552889_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1552889_a_at (1552889_a_at) across 6674 perturbations tested by GENEVESTIGATOR:
atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):-1.8372593Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (non-lesional; whole skin) |
| Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
adrenal gland cancer study 4 / normal adrenal cortex tissue
Relative Expression (log2-ratio):-1.8018923Number of Samples:43 / 4
| Experimental | adrenal gland cancer study 4 |
| Primary tumor tissue samples of the adrenal cortex from patients with adrenocortical carcinoma (ACC). | |
| Control | normal adrenal cortex tissue |
| Histological normal adrenal gland cortical tissue samples derived after autopsy. |
stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):-1.6494818Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):-1.5119123Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (lesional; whole skin) |
| Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):-1.3582001Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):1.1982031Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
renal cell carcinoma study 5 (papillary type) / normal kidney tissue (adult)
Relative Expression (log2-ratio):-1.0889473Number of Samples:19 / 3
| Experimental | renal cell carcinoma study 5 (papillary type) |
| Tumor tissue samples from the kidney of patients with papillary renal cell carcinoma (pRCC). | |
| Control | normal kidney tissue (adult) |
| Normal adult kidney tissue samples. |
breast cancer study 8 (metastatic) / normal breast tissue
Relative Expression (log2-ratio):1.0539417Number of Samples:2 / 4
| Experimental | breast cancer study 8 (metastatic) |
| Human metastatic infiltrating ductal carcinoma sample of the breast derived from lymph nodes of a female patient with breast cancer. | |
| Control | normal breast tissue |
| Normal human breast samples of healthy female individuals. |
Duchenne muscular dystrophy study 5 (moderate) / Becker muscular dystrophy study 2 (moderate)
Relative Expression (log2-ratio):0.99490356Number of Samples:4 / 3
| Experimental | Duchenne muscular dystrophy study 5 (moderate) |
| Biopsies of vastus lateralis muscle from male patients with Duchenne muscular dystrophy and moderate fibrotic replacement. All subjects showed evidence of a dystrophic process (degeneration/regeneration of muscle fibers) and absence of dystrophin. | |
| Control | Becker muscular dystrophy study 2 (moderate) |
| Biopsies of vastus lateralis muscle from male patients with Becker muscular dystrophy and moderate fibrotic replacement. All subjects showed evidence of a dystrophic process (degeneration/regeneration of muscle fibers) and abnormal dystrophin. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):0.99132824Number of Samples:12 / 20
| Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |